{"nctId":"NCT03888066","briefTitle":"Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)","startDateStruct":{"date":"2019-04-24","type":"ACTUAL"},"conditions":["Hyperkalemia"],"count":1195,"armGroups":[{"label":"Group 1: Patiromer","type":"EXPERIMENTAL","interventionNames":["Drug: Patiromer"]},{"label":"Group 2: Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebos"]}],"interventions":[{"name":"Patiromer","otherNames":["Veltassa"]},{"name":"Placebos","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age at least 18 years or greater\n* Symptomatic low ejection fraction heart failure (weak heart muscle)\n* Receiving any dose of a beta blocker for the treatment of HF (unless not able to tolerate)\n* Kidney function not more than mild or moderately impaired\n* High blood potassium (\\>5.0 mEq/L) currently while receiving medications for heart failure OR normal blood potassium currently but previously had high potassium in the12 months prior to screening which caused a permanent reduction or discontinuation of heart failure medications\n* Hospitalization for heart failure or treatment in an out patient setting with intravenous medications within the last 12 months before screening.\n\nExclusion Criteria:\n\n* Current acute decompensated HF, within 4 weeks before screening. Subjects with a discharge from a hospitalization for acute decompensation of HF longer than 4 weeks before screening may be included\n* Significant primary aortic or mitral valvular heart disease (except secondary mitral regurgitation due to left ventricular dilatation)\n* Heart transplantation or planned heart transplantation (i.e., currently on a heart transplant waiting list) during the study period","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Changes in Serum K+ Levels From Baseline","description":"Adjusted mean changes in serum K+ from Baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.029","spread":"0.019"},{"groupId":"OG001","value":"0.127","spread":"0.019"}]}]}]},{"type":"SECONDARY","title":"CIF Estimates of the Time to First Hyperkalemia Event With Serum K+ Level > 5.5 mEq/l Over Time","description":"Cumulative incidence of the first event of hyperkalemia with a serum K+ value \\>5.5 mEq/l taking death as competing and calculated as CIF Estimates (95% CI) over time.\n\nAalen-Johansen estimators of the cumulative incidence function with death as a competing event.\n\nCIF = cumulative incidence function; mEq/l = Milliequivalents Per Liter","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":null},{"groupId":"OG001","value":"0.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":null},{"groupId":"OG001","value":"0.08","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":null},{"groupId":"OG001","value":"0.10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":null},{"groupId":"OG001","value":"0.14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":null},{"groupId":"OG001","value":"0.20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.17","spread":null},{"groupId":"OG001","value":"0.24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.21","spread":null},{"groupId":"OG001","value":"0.29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":null},{"groupId":"OG001","value":"0.34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":null},{"groupId":"OG001","value":"0.34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.34","spread":null},{"groupId":"OG001","value":"0.34","spread":null}]}]}]},{"type":"SECONDARY","title":"CIF Estimates of the Reduction of the MRA Dose Below Target Dose Over Time","description":"Cumulative incidence of the reduction of the MRA dose below target dose calculated as CIF Estimates (95% CI) over time.\n\nNote: The reduction below the MRA target dose must last for at least 14 days (orless if at the end of study) to confirm this endpoint.\n\nCIF = cumulative incidence function; mEq/l = Milliequivalents Per Liter","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":null},{"groupId":"OG001","value":"0.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":null},{"groupId":"OG001","value":"0.08","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":null},{"groupId":"OG001","value":"0.12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","spread":null},{"groupId":"OG001","value":"0.15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.14","spread":null},{"groupId":"OG001","value":"0.19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.16","spread":null},{"groupId":"OG001","value":"0.23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.19","spread":null},{"groupId":"OG001","value":"0.26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.22","spread":null},{"groupId":"OG001","value":"0.27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.27","spread":null},{"groupId":"OG001","value":"0.29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.27","spread":null},{"groupId":"OG001","value":"0.29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.27","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Investigator-reported Events of Hyperkalemia","description":"Participant's follow-up is from the date of the first dose of randomized study medication up to the participant's end of study date or 24 Jun 2021, whichever comes first.\n\nAnnualized event rate per 100 subject-years= The total number of events for all subjects in the treatment group divided by the total subject-years of follow-up in that treatment group multiplied by 100.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.38","spread":null},{"groupId":"OG001","value":"114.65","spread":null}]}]}]},{"type":"SECONDARY","title":"Hyperkalemia-related Hard Outcomes Endpoints","description":"Analyzed using Win Ratio approach with the following hierarchical components:\n\n1. Time to CV death\n2. Total number of CV hospitalizations\n3. Total number of hyperkalemia toxicity events with serum K+ \\>6.5 mEq/l\n4. Total number of hyperkalemia events with serum K+ \\>6.0-6.5 mEq/l\n5. Total number of hyperkalemia events with serum K+ \\>5.0 mEq/l\n\nMHTE=More hyperkalemia toxicity events; MHE=More hyperkalemia events; CV=Cardiovascular","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3491","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4609","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4539","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4178","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"419","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"401","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4283","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1446","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55633","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34156","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79566","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"192721","spread":null}]}]}]},{"type":"SECONDARY","title":"RAASi Use Score","description":"RAASi use score (0 to 8 points) analyzed using the Win Ratio approach for each pair of participants with the following additive components:\n\n1. All-cause death\n2. Occurrence of a CV hospitalization\n3. HF medication use and dose for i) an ACEi/ARB/ARNi, ii) a MRA, and iii) a beta-blocker\n\nEach participant in each comparison can have 0-8 points and all participants are compared using this score at the respective appropriate follow-up time point.\n\nRAASi=renin-angiotensin-aldosterone system inhibitor; ACEi=angiotensin converting enzyme inhibitor; ARB=angiotensin receptor blocker; ARNi=angiotensin receptor/neprilysin inhibitor; MRA=mineralocorticoid receptor antagonist.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62073","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49733","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80915","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"192721","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":54,"n":439},"commonTop":["Hyperkalaemia","Hypokalaemia","Hypomagnesaemia","Diarrhoea","Hypotension"]}}}